Identification

Name
Levomethadyl Acetate
Accession Number
DB01227  (APRD00745)
Type
Small Molecule
Groups
Approved, Investigational
Description

A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem]

Structure
Thumb
Synonyms
  • (-)-alpha-Acetylmethadol
  • (1S,4S)-4-(dimethylamino)-1-Ethyl-2,2-diphenylpentyl acetate
  • 1-alpha-Acetylmethadol
  • LAAM
  • Levacetilmetadol
  • Levacetylmethadol
  • Levacetylmethadolum
  • Levo-alpha-acetylmethadol
  • Levo-methadyl acetate
  • Levo-α-acetylmethadol
  • Levomethadyl
  • Levomethadyl acetate
Product Ingredients
IngredientUNIICASInChI Key
Levomethadyl acetate hydrochlorideB54CW5KG5243033-72-3UXBPQRGCVJOTNT-COBSGTNCSA-N
International/Other Brands
Orlaam
Categories
UNII
R3B637Y991
CAS number
1477-40-3
Weight
Average: 353.4977
Monoisotopic: 353.235479241
Chemical Formula
C23H31NO2
InChI Key
XBMIVRRWGCYBTQ-AVRDEDQJSA-N
InChI
InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
IUPAC Name
(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl acetate
SMILES
CC[[email protected]](OC(C)=O)C(C[[email protected]](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.

Structured Indications
Not Available
Pharmacodynamics

Levomethadyl acetate (also known as LAAM) is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, levomethadyl acetate is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. In this respect, the drug is similar to Methadone and also has structural similarities to it. The levomethadyl acetate abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.

Mechanism of action

Opiate receptors (Mu, Kappa, Delta) are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Levomethadyl acetate effectively opens calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist), resulting in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
UNeuronal acetylcholine receptor subunit beta-4
other/unknown
Human
UNeuronal acetylcholine receptor subunit alpha-3
antagonist
Human
Absorption

Levomethadyl acetate is rapidly absorbed from an oral solution.

Volume of distribution
Not Available
Protein binding

Approximately 80%

Metabolism

Levomethadyl acetate undergoes extensive first-pass metabolism to the active demethylated metabolite nor-levomethadyl acetate, which is further demethylated to a second active metabolite, dinor-levomethadyl acetate. These metabolites are more potent than the parent drug.

Route of elimination
Not Available
Half life

2.6 days

Clearance
Not Available
Toxicity

Signs of overdose include apnea, circulatory collapse, pulmonary edema, cardiac arrest, and death.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Levomethadyl Acetate Metabolism PathwayDrug metabolism
Levomethadyl Acetate Action Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Levomethadyl Acetate.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levomethadyl Acetate.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Agomelatine.Approved, Investigational
AlaproclateLevomethadyl Acetate may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Levomethadyl Acetate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levomethadyl Acetate.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Levomethadyl Acetate.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomethadyl Acetate.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amiloride.Approved
AmiodaroneThe metabolism of Levomethadyl Acetate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Levomethadyl Acetate which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levomethadyl Acetate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Levomethadyl Acetate.Approved
AprepitantThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomethadyl Acetate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levomethadyl Acetate.Approved
AtazanavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Levomethadyl Acetate can be decreased when combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Levomethadyl Acetate.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levomethadyl Acetate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Levomethadyl Acetate.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azaperone.Investigational, Vet Approved
AzelastineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Levomethadyl Acetate.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Levomethadyl Acetate.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levomethadyl Acetate.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benzyl alcohol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Levomethadyl Acetate.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Levomethadyl Acetate.Investigational
BoceprevirThe metabolism of Levomethadyl Acetate can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Levomethadyl Acetate.Experimental
BortezomibThe metabolism of Levomethadyl Acetate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levomethadyl Acetate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brotizolam.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomethadyl Acetate.Approved, Investigational
BuprenorphineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomethadyl Acetate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomethadyl Acetate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levomethadyl Acetate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Canertinib.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Levomethadyl Acetate can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Caroxazone.Withdrawn
CeritinibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomethadyl Acetate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levomethadyl Acetate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomethadyl Acetate.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levomethadyl Acetate.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Levomethadyl Acetate.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Levomethadyl Acetate.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levomethadyl Acetate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomethadyl Acetate.Approved, Vet Approved
CitalopramLevomethadyl Acetate may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Levomethadyl Acetate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Levomethadyl Acetate can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clobazam.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clofenamide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonidine.Approved
ClopamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clopamide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomethadyl Acetate.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clorexolone.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levomethadyl Acetate.Approved
CobicistatThe metabolism of Levomethadyl Acetate can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levomethadyl Acetate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levomethadyl Acetate.Approved, Illicit
ConivaptanThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Levomethadyl Acetate can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levomethadyl Acetate.Approved
CyclosporineThe metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomethadyl Acetate.Approved
DapoxetineLevomethadyl Acetate may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levomethadyl Acetate.Approved, Investigational
DarunavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Levomethadyl Acetate can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomethadyl Acetate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.Approved
DesvenlafaxineLevomethadyl Acetate may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Levomethadyl Acetate.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomethadyl Acetate.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levomethadyl Acetate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Levomethadyl Acetate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levomethadyl Acetate.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levomethadyl Acetate.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Levomethadyl Acetate.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levomethadyl Acetate.Approved, Illicit
DihydroergotamineThe metabolism of Levomethadyl Acetate can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Levomethadyl Acetate can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomethadyl Acetate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levomethadyl Acetate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Levomethadyl Acetate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Illicit
DronedaroneThe metabolism of Levomethadyl Acetate can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Drotebanol.Experimental, Illicit
DuloxetineLevomethadyl Acetate may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efonidipine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Eltanolone.Investigational
EluxadolineLevomethadyl Acetate may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Levomethadyl Acetate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levomethadyl Acetate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Eplerenone.Approved
ErythromycinThe metabolism of Levomethadyl Acetate can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramLevomethadyl Acetate may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levomethadyl Acetate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomethadyl Acetate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Levomethadyl Acetate.Experimental
EthanolLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomethadyl Acetate.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Levomethadyl Acetate.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.Approved
EtoperidoneLevomethadyl Acetate may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Levomethadyl Acetate.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fenquizone.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomethadyl Acetate.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levomethadyl Acetate.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flunitrazepam.Approved, Illicit
FluoxetineLevomethadyl Acetate may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomethadyl Acetate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomethadyl Acetate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levomethadyl Acetate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Levomethadyl Acetate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Levomethadyl Acetate can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomethadyl Acetate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Gabapentin Enacarbil.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Levomethadyl Acetate.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Levomethadyl Acetate.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levomethadyl Acetate.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Levomethadyl Acetate.Experimental
GepironeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Levomethadyl Acetate.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levomethadyl Acetate.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomethadyl Acetate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Levomethadyl Acetate.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Levomethadyl Acetate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Levomethadyl Acetate.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydracarbazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levomethadyl Acetate.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Levomethadyl Acetate.Approved
IbopamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ibopamine.Experimental
IdelalisibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iloperidone.Approved
ImatinibThe metabolism of Levomethadyl Acetate can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Imipramine.Approved
IndalpineLevomethadyl Acetate may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Indapamide.Approved
IndinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Levomethadyl Acetate.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate.Approved
IproclozideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Levomethadyl Acetate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levomethadyl Acetate.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Isosorbide.Approved, Investigational
IsradipineThe metabolism of Levomethadyl Acetate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomethadyl Acetate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levomethadyl Acetate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levodopa.Approved
LevomilnacipranLevomethadyl Acetate may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levomethadyl Acetate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levomethadyl Acetate.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lofentanil.Illicit
LopinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levomethadyl Acetate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lormetazepam.Approved
LovastatinThe metabolism of Levomethadyl Acetate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levomethadyl Acetate.Approved
LuliconazoleThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Levomethadyl Acetate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levomethadyl Acetate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Maprotiline.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Levomethadyl Acetate.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mebicar.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levomethadyl Acetate.Approved
MeclizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Medetomidine.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mefruside.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levomethadyl Acetate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Melperone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Levomethadyl Acetate.Investigational
MephentermineMephentermine may increase the analgesic activities of Levomethadyl Acetate.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomethadyl Acetate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Levomethadyl Acetate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Levomethadyl Acetate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Levomethadyl Acetate.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomethadyl Acetate.Approved
MethotrimeprazineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomethadyl Acetate.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Levomethadyl Acetate.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomethadyl Acetate.Approved
MeticraneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Levomethadyl Acetate.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone.Approved
MetyrosineLevomethadyl Acetate may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Levomethadyl Acetate.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranLevomethadyl Acetate may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
MirtazapineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Levomethadyl Acetate.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Levomethadyl Acetate.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levomethadyl Acetate.Approved
NaltrexoneThe therapeutic efficacy of Levomethadyl Acetate can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Levomethadyl Acetate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Levomethadyl Acetate can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nialamide.Withdrawn
NilotinibThe metabolism of Levomethadyl Acetate can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomethadyl Acetate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levomethadyl Acetate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate.Approved, Investigational
OlaparibThe metabolism of Levomethadyl Acetate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levomethadyl Acetate.Approved
OpiumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Opium.Approved, Illicit
OrphenadrineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Levomethadyl Acetate.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomethadyl Acetate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Oxethazaine.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Levomethadyl Acetate.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomethadyl Acetate.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levomethadyl Acetate.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levomethadyl Acetate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levomethadyl Acetate.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Levomethadyl Acetate.Approved
PalbociclibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levomethadyl Acetate.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levomethadyl Acetate.Approved
ParaldehydeLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pargyline.Approved
ParoxetineLevomethadyl Acetate may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levomethadyl Acetate.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levomethadyl Acetate.Approved, Vet Approved
PentobarbitalThe metabolism of Levomethadyl Acetate can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Levomethadyl Acetate.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
PerazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levomethadyl Acetate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levomethadyl Acetate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenelzine.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Levomethadyl Acetate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Levomethadyl Acetate can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Levomethadyl Acetate.Approved, Illicit
PhenytoinThe metabolism of Levomethadyl Acetate can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Levomethadyl Acetate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levomethadyl Acetate.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levomethadyl Acetate.Approved
PiretanideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleLevomethadyl Acetate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levomethadyl Acetate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levomethadyl Acetate.Approved
PrimidoneThe metabolism of Levomethadyl Acetate can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levomethadyl Acetate.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomethadyl Acetate.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levomethadyl Acetate.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levomethadyl Acetate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Levomethadyl Acetate.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomethadyl Acetate.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Levomethadyl Acetate.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Levomethadyl Acetate.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levomethadyl Acetate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Levomethadyl Acetate.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levomethadyl Acetate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomethadyl Acetate.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Levomethadyl Acetate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ramelteon.Approved, Investigational
RamosetronLevomethadyl Acetate may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe metabolism of Levomethadyl Acetate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levomethadyl Acetate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levomethadyl Acetate.Approved, Investigational
RifabutinThe metabolism of Levomethadyl Acetate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Levomethadyl Acetate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Levomethadyl Acetate can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomethadyl Acetate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Levomethadyl Acetate.Investigational
RitonavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Ritonavir.Approved, Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Romifidine.Vet Approved
RopiniroleLevomethadyl Acetate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomethadyl Acetate.Approved
RotigotineLevomethadyl Acetate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levomethadyl Acetate.Approved
SafrazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levomethadyl Acetate.Approved, Vet Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomethadyl Acetate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineLevomethadyl Acetate may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomethadyl Acetate.Approved, Vet Approved
SildenafilThe metabolism of Levomethadyl Acetate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Levomethadyl Acetate.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Levomethadyl Acetate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.Approved, Investigational
SulfisoxazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomethadyl Acetate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sultopride.Experimental
SuvorexantLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Levomethadyl Acetate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Levomethadyl Acetate can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomethadyl Acetate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrodotoxin.Investigational
ThalidomideLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Theobromine.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomethadyl Acetate.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Levomethadyl Acetate.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Levomethadyl Acetate.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomethadyl Acetate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levomethadyl Acetate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levomethadyl Acetate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Levomethadyl Acetate can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tilidine.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Levomethadyl Acetate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Levomethadyl Acetate.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levomethadyl Acetate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levomethadyl Acetate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomethadyl Acetate.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomethadyl Acetate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomethadyl Acetate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Levomethadyl Acetate.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Levomethadyl Acetate.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Levomethadyl Acetate.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triprolidine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Levomethadyl Acetate.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Levomethadyl Acetate.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Levomethadyl Acetate.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levomethadyl Acetate.Approved
UlaritideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ularitide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levomethadyl Acetate.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levomethadyl Acetate.Approved
VenlafaxineThe metabolism of Levomethadyl Acetate can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Veralipride.Experimental
VerapamilThe metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Xenon.Experimental
XipamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomethadyl Acetate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ziconotide.Approved
ZimelidineLevomethadyl Acetate may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zolazepam.Vet Approved
ZolpidemLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levomethadyl Acetate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomethadyl Acetate.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15358
KEGG Drug
D04716
KEGG Compound
C08012
PubChem Compound
15130
PubChem Substance
46507749
ChemSpider
14401
ChEBI
6441
ChEMBL
CHEMBL1514
Therapeutic Targets Database
DAP001139
PharmGKB
PA450215
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Levomethadyl_Acetate
ATC Codes
N07BC03 — Levacetylmethadol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders1
2CompletedTreatmentOpioid-Related Disorders / Substance-Related Disorders1
4CompletedTreatmentOpioid-Related Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility>15 mg/mLNot Available
logP5.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00179 mg/mLALOGPS
logP4.78ALOGPS
logP4.88ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity117.86 m3·mol-1ChemAxon
Polarizability40.53 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9648
Caco-2 permeable+0.7459
P-glycoprotein substrateSubstrate0.5822
P-glycoprotein inhibitor IInhibitor0.8472
P-glycoprotein inhibitor IINon-inhibitor0.8897
Renal organic cation transporterNon-inhibitor0.6473
CYP450 2C9 substrateNon-substrate0.7976
CYP450 2D6 substrateNon-substrate0.8641
CYP450 3A4 substrateSubstrate0.6658
CYP450 1A2 substrateInhibitor0.5619
CYP450 2C9 inhibitorNon-inhibitor0.8153
CYP450 2D6 inhibitorInhibitor0.7123
CYP450 2C19 inhibitorNon-inhibitor0.7312
CYP450 3A4 inhibitorInhibitor0.5242
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5811
Ames testNon AMES toxic0.9016
CarcinogenicityCarcinogens 0.7025
BiodegradationNot ready biodegradable0.9792
Rat acute toxicity3.3406 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9706
hERG inhibition (predictor II)Inhibitor0.7157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Aralkylamines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Diphenylmethane / Aralkylamine / Amino acid or derivatives / Carboxylic acid ester / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Amine / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, acetate ester (CHEBI:6441)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB: Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem. 1997 Nov 14;272(46):28869-74. [PubMed:9360954]
  2. Skoulis NP, James RC, Harbison RD, Roberts SM: Depression of hepatic glutathione by opioid analgesic drugs in mice. Toxicol Appl Pharmacol. 1989 Jun 1;99(1):139-47. [PubMed:2471291]
  3. Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. [PubMed:10911931]
  4. Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71. [PubMed:11561100]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB4
Uniprot ID
P30926
Uniprot Name
Neuronal acetylcholine receptor subunit beta-4
Molecular Weight
56378.985 Da
References
  1. Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71. [PubMed:11561100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA3
Uniprot ID
P32297
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-3
Molecular Weight
57479.54 Da
References
  1. Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71. [PubMed:11561100]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Oda Y, Kharasch ED: Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001 Sep;298(3):1021-32. [PubMed:11504799]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 02:57